CRISPR Therapeutics (NASDAQ:CRSP) said Monday that Vertex Pharmaceuticals (VRTX) subsidiary ViaCyte has elected to opt-out of their development partnership for gene-edited stem cell therapies for the ...
Scientists have successfully transplanted gene-edited insulin-producing cells into a man with type 1 diabetes—allowing him to ...
These companies could innovate their way to success.
While most of the attention on CRISPR Therapeutics centers on the company’s Vertex-partnered cell therapy and looming FDA advisory committee meeting, Alex Harding, M.D., is cooking up the biotech's ...
Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...
Dr. Musunuru and Dr. Ahrens-Nicklas holding KJ post infusion Senior Correspondent Gene therapy has always held enormous promise to correct genetic diseases, but turning that potential into treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback